BURKITT LYMPHOMA TREATMENT MARKET ANALYSIS
Competitive Analysis
Key players in this market are offering products to cater to the rising unmet needs of patients suffering from relapsed or refractory Burkitt lymphoma. For instance, Servier, in collaboration with Pfizer Inc., initiated Phase 1 study in 2015 for gene-edited allogeneic CAR19 T-cells (UCART19) to treat relapsed/ refractory acute lymphoblastic leukemia (ALL) in pediatric patients.
Key players operating in the global Burkitt lymphoma treatment market include Novartis AG, Sanofi Pasteur, Eisai Inc., Cellerant Therapeutics, Inc., Pfizer, Inc., Merck KGaA, Seattle Genetics, Inc., Karyopharm Therapeutics, Inc., Boehringer Ingelheim GmbH, and AbbVie Inc.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
